Latest Biotechnology News

Page 7 of 101
Nyrada has received supportive written feedback from the US FDA on its proposed pathway for taking Xolatryp into a US Phase IIa heart-attack trial. The regulator identified no major issues, but additional information and stability data are still required before the planned IND submission in the first half of 2027.
Ada Torres
Ada Torres
13 Oct 2026
Mesoblast has reported a sharp commercial step-up in FY2026, with Ryoncil generating US$115.2 million in net sales and total revenue reaching US$120.3 million. The company has also completed treatment in its 350-patient back-pain trial and refinanced its debt, but remains loss-making and expects to need more capital beyond the next 12 months.
Ada Torres
Ada Torres
12 Oct 2026
Nyrada has lodged a prospectus for approximately 10.74 million free options linked to its recent capital raising, giving eligible CDI holders three options for every four CDIs issued. The options carry a $0.93 exercise price and could generate almost $10 million if fully exercised, although that cash remains contingent on holder participation.
Ada Torres
Ada Torres
12 Oct 2026
Cynata Therapeutics has launched a fully underwritten $913,000 entitlement offer as it reassesses the future of its Cymerus platform after two major trials failed to demonstrate efficacy. The raise provides short-term funding, but the prospectus warns that further capital may be needed and repeats a material uncertainty over going concern.
Ada Torres
Ada Torres
8 Oct 2026
Noxopharm says the FDA has supported its proposed Phase II design and chemical manufacturing strategy for SOF-SKN, its topical treatment candidate for cutaneous lupus erythematosus. The feedback improves regulatory clarity, but the trial remains targeted for the first half of calendar 2028 and is subject to further studies and regulatory requirements.
Ada Torres
Ada Torres
8 Oct 2026
Arovella Therapeutics has released a second clinical batch of its off-the-shelf CAR-iNKT therapy ALA-101, with material expected to support dose escalation and the start of dose expansion in blood cancers. The company is also adding hospital sites ahead of anticipated first-patient dosing in late October.
Ada Torres
Ada Torres
7 Oct 2026
The FDA says positive results from Neurizon’s HEALEY ALS trial could potentially support traditional approval of NUZ-001, with the study possibly serving as the sole registrational trial. The guidance is conditional, but gives the company a clearer regulatory route ahead of topline results expected in late Q2 2027.
Ada Torres
Ada Torres
6 Oct 2026
Neurotech International has moved NTI164 into a registration-enabling Phase III autism trial, but its annual report carries a material going-concern warning. The company says post-year-end debt and equity funding should support the program through topline data, subject to execution and completion.
Ada Torres
Ada Torres
5 Oct 2026
AdAlta and Shanghai Cell Therapy Group have approved the FDA briefing pack and manufacturing transfer plan for EW-001, bringing the mesothelioma CAR-T therapy closer to an Australian Phase 1 trial. The FDA meeting is scheduled for November, while two Chinese patients remain under follow-up, including a second complete responder.
Ada Torres
Ada Torres
5 Oct 2026
Chimeric Therapeutics remains suspended from ASX trading after failing to lodge its FY2026 financial statements, with the company reporting an approximate $7.7 million net asset deficiency and unresolved creditor negotiations. Potential recapitalisation interest has emerged, but no binding funding or settlement agreement has been reached.
Ada Torres
Ada Torres
1 Oct 2026
Imagion Biosystems has secured central ethics approval for its US Phase 1b/2 trial of the MagSense HER2 imaging agent, removing a key requirement before recruitment can begin. Site activation is now underway, but no patient has yet been enrolled and the announcement provides no clinical data.
Ada Torres
Ada Torres
30 Sept 2026
Paradigm Biopharmaceuticals has entered voluntary administration after its pivotal Phase 3 trial produced an interim efficacy result below the threshold required for continuation. The company’s securities will remain suspended while administrators assess its viability, liabilities and possible restructuring options.
Ada Torres
Ada Torres
30 Sept 2026

Browse the archive

Full archive